Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Drug utilisation pattern and off-label use of medicines in Estonian neonatal units.European journal of clinical pharmacology · 2011
   Article
2. Modelling and simulation as research tools in paediatric drug development.European journal of clinical pharmacology · 2011 · on this map
   Review
3. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children.Clinical pharmacokinetics · 2011
   Article
4. Can we get the necessary clinical trials in children and avoid the unnecessary ones?European journal of clinical pharmacology · 2009
   Article

Corrections and comments

• Comment on
  Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as